{
  "docId": "019de074-7bfd-70c0-985e-370853614892",
  "docSlug": "be9cd2ecd1a9b4702566620e9f2aa170",
  "documentTitle": "Bionomics | Results Presentation Deck | 27 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 27,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The chart uses a layered pie/segmentation visual to show the total addressable population vs. the specific opportunity for BNC210.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7bfd-70c0-985e-370853614892/9",
  "deckHref": "/decks/019de074-7bfd-70c0-985e-370853614892",
  "deckJsonHref": "/decks/019de074-7bfd-70c0-985e-370853614892.json",
  "deckAnchorHref": "/decks/019de074-7bfd-70c0-985e-370853614892#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.31,
        "x": 0.65,
        "y": 0.17
      },
      "kind": "chart",
      "text": "Market segmentation of SAD prevalence: 31M lifetime, 18M adult prevalence, 7M with symptoms >10 years (Opportunity for BNC210)",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8e92be0-8bfb-42d1-aa32-2493ea71a4c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.06,
        "y": 0.25
      },
      "kind": "list",
      "text": "Social Anxiety Disorder (SAD), or Social Phobia, is a significant and persistent fear of social and performance-related situations. Includes anxiety from everyday social situations; a reoccurring episodic disorder. Amongst the largest mental health conditions with lifetime prevalence affecting >31M Americans. Triggers that exacerbate anxiety can occur at any time",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb97c52d-ea7e-4024-a3bc-ff6eef8e4582",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.08,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Sources: US Census Bureau, NIMH, Anxiety and Depression Association of America (ADAA).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54a08366-262c-4494-9c6a-5f23945d7a65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.58,
        "x": 0.04,
        "y": 0.13
      },
      "kind": "title",
      "text": "No FDA-approved fast-acting medications for as-needed treatment",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b48d4e1c-a3f4-4433-a657-0d670cfa7bf0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "Social Anxiety Disorder Represents a Large Segment of the Anxiety Market",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "020312a3-3d41-438a-85ea-0758fbad191b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "47e8fb62-3ac0-4a60-8ce9-9644059b6e51",
      "evidence": "Market segmentation of SAD prevalence: 31M lifetime, 18M adult prevalence, 7M with symptoms >10 years (Opportunity for BNC210)",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "1e9122e8-6cc3-4704-b2ab-4249699a63cb",
      "evidence": "The slide segments the total population into smaller, more specific addressable market segments.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 5,
      "beatId": "a91f66d9-76dd-4ada-991d-a8d5ac9d7e1b",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document highlights the challenges of current treatments and the impact of anxiety disorders on patients.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 5,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "c2bcb376-37fc-4ae2-8d27-0ff27bc7cd15",
      "evidence": "The document presents before-after comparisons of BNC210's effects on α7 receptors and anxiety symptoms.",
      "position": 0,
      "objective": "To demonstrate BNC210's ability to modulate α7 receptors and reduce anxiety symptoms",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.8,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}